ABC has published an article on a study led by Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This work has unravelled the mechanism of action of the mAb806 antibody, a drug used to treat glioblastoma. Published in the journal PNAS, the study lays the foundation for the extension of this treatment to more types of tumours and to more specific therapies.
Link to ABC
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).